Identifying Predictive Biomarkers for Immuno-Oncology Therapeutics

Time: 4:15 pm
day: Track A - Day 1 pm


• Given the large number of novel IO agents and combination clinical trials being run, what is needed to harmonize biomarkers for the medical community?
• Where is progress being made in developing analytically and clinically validated assays?
• What impact does new predictive biomarker identification have on commercial potential of novel therapeutics?